Mandate

Vinge advises Procuritas on its acquisition of We Select

Vinge advises Procuritas Capital Investors in connection with its acquisition of a majority stake in The We Select Company AB (“We Select”), a fast-growing digital talent acquisition platform. Key management will retain significant ownership of the company after the transaction.

We Select was founded in 2011 as a traditional recruitment services company. After launching its digital talent attraction offering in 2016, the company quickly transformed its business model and focused entirely on the fast-growing talent acquisition segment – social media. We Select helps companies to attract and hire top talent easily by combining strategic employer branding, data-driven job advertising and automatic candidate management in one smart platform.

Vinge’s team mainly consisted of Jonas Johansson, Carl Sander, Linus Adolfsson (M&A), Seyran Sahin, Karl-Gustaw Tobola (Banking and Finance), Elin Broman (Employment), Arvid Axelryd, Anna Högsten (IP), Lisa Hörnqvist (IT & GDPR), Kristoffer Sällfors (Public Procurement) and Anna Ekdahl Roos (Project Assistant).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026